PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$8.91
-0.24 (-2.62%)
Open$8.65
Previous Close$9.15
Day High$9.06
Day Low$8.41
52W High$14.76
52W Low$3.01
Volume—
Avg Volume15.68M
Market Cap3.42B
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+90.2% upside
Current
$8.91
$8.91
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.16M | 243.91M | 233.99M |
| Net Income | — | 21.63M | 22.04M |
| Profit Margin | — | 8.9% | 9.4% |
| EBITDA | — | 48.94M | 46.22M |
| Free Cash Flow | — | 24.46M | 20.15M |
| Rev Growth | — | -3.3% | +11.1% |
| Debt/Equity | — | 0.58 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |